In vivo hepatic gene therapy

Area of Science:

• Molecular Biology
• Hepatology
• Gene Therapy

Background:

• Gene therapy aims to treat diseases by correcting genetic abnormalities at the molecular level.
• Hepatic gene therapy specifically targets liver diseases, including inherited disorders, metabolic conditions, liver cancer, and viral hepatitis.

Purpose of the Study:

• To review the strategies and vector systems employed in hepatic gene therapy.
• To highlight the potential of gene therapy for treating liver-related and systemic diseases like hemophilia.

Main Methods:

• Categorization of hepatic gene therapy into ex vivo and in vivo approaches.
• Discussion of viral vectors (retrovirus, lentivirus, adenovirus, adeno-associated virus, baculovirus) and non-viral vectors (liposome, liver-specific ligand, naked nucleotide) for gene transfer.
• Description of ex vivo method involving hepatocyte harvesting, gene introduction, and retransplantation.
• Description of in vivo method involving local or systemic administration of vectors.

Main Results:

• Both ex vivo and in vivo strategies are viable for hepatic gene therapy.
• A range of viral and non-viral vectors have been explored for efficient liver-directed gene transfer.
• Current vector technologies, both viral and non-viral, have limitations.

Conclusions:

• Hepatic gene therapy holds significant potential for treating a spectrum of liver and systemic diseases.
• Ongoing research and modification of existing vectors are crucial for developing improved next-generation liver-directed gene transfer systems.